Cognitive Interference Processing


Brain / Nervous System

Cognitive Interference Processing
Pediatric ADHD, MS, Depression

Brain / Nervous System

Cognitive Interference Processing
INDICATION(S):Pediatric ADHD, MS, Depression
STAGE:Phase 3
Cognitive therapeutics, assessments, and diagnostics

Our affiliate Akili is developing a new category of prescription digital medicines, delivered not through a pill but through a high-quality action video game experience. Our aim is to develop a digital intervention that targets “interference processing” through a proprietary mechanism with adaptive algorithms allowing instant personalization. We are advancing a broad pipeline of programs to treat cognitive deficiency and improve symptoms associated with medical conditions across neurology and psychiatry, including attention-deficit hyperactivity disorder (ADHD), major depressive disorder (MDD), Parkinson’s disease (PD), autism spectrum disorder (ASD) and multiple sclerosis (MS) and various inflammatory diseases. AKL-T01, our lead product candidate from the Project:EVOTM platform, successfully showed a statistically significant improvement compared to an active control (p=0.006) in a pivotal study in patients with pediatric ADHD.

  • Patient Need & Market Potential
    • There are a number of conditions where the brain’s executive function is negatively impacted, including ADHD, autism, Alzheimer’s disease, and depression. The markets for treatment of these conditions all have significant needs in terms of risk-benefit profiles, and are currently only partially served by centrally-acting drugs with challenging safety profiles or by in-person behavioral therapy
    • The market for ADHD therapeutics is projected to be approximately $10 billion by 2020 and we believe that this market – and the other markets in which our Cognitive Interference Processing products may act as a stand-alone medical treatment, add-on therapy, or digital biomarker – represent significant opportunities for the program
  • Our Approach to Solving the Problem
    • Our technology is non-invasive and built to be patient-friendly, while designed to have a potent treatment effect
    • By leveraging medical-grade science and consumer-grade software technology, we are seeking to produce a new type of medical product that can offer safe and effective scalable treatment and better monitoring for patients across a range of mental health and neurological conditions
  • Intellectual Property
    • We currently own or have exclusive rights to a total of 25 issued patents and patent applications in 13 families or patent filings
    • One of these 13 families of IP is exclusively licensed from UCSF and covers our cognitive assessment and treatment methods related to interference processing.
  • Team
    • Our cross-disciplinary team has expertise in neuroscience, clinical trials in related disorders, video game design, data science, and consumer engagement
    • Key Advisors include:

      Dr. Adam Gazzaley, the Founding Director of Neuroscape Lab at UCSF;

      Dr. Daphne Bavelier, Professor of Cognitive Neuroscience at the University of Geneva, and of Brain and Cognitive Sciences at the University of Rochester;

      Dr. Stephen Faraone, Professor in the Departments of Psychiatry and Neuroscience & Physiology at SUNY Upstate Medical University and Director of Medical Genetics Research for the University;

      Dr. Robert Schultz, Professor of Psychology in the Department of Pediatrics at the University of Pennsylvania School of Medicine; and

      Dr. Geraldine Dawson, Professor, Departments of Psychiatry and Behavioral Sciences, Pediatrics, and Psychology, and Neuroscience and Director of the Duke Center for Autism and Brain Development at Duke University

    • The program was developed and is run by Dr. Eddie Martucci and team members, Mr. Matthew Omernick, Mr. LeRoux Jooste, and Mr. Scott Kellogg
  • Milestones Achieved
    • We achieved the primary endpoint in a pivotal study of an investigational digital medicine for pediatric ADHD and announced topline results in 4Q 2017. AKL-T01, the lead investigational digital medicine from the Project:EVOTM platform, successfully showed a statistically significant improvement compared to an active control (p = 0.006) on the predefined primary endpoint, a composite score from the Test of Variables of Attention (T.O.V.A.®), an objective measure of sustained attention and inhibitory control.
    • Academic investigators recently published two pilot research studies in peer-reviewed journals showing the potential benefit of our core cognitive treatment technology in targeting cognition and mood in depressed individuals.
    • Our cognitive interference targeting technology has also been further studied, with additional efficacy data and symptom benefit, in a group of children with sensory processing and attention impairments.
    • Proof-of-concept treatment data on the Akili technology was established as the cover story in the top tier medical science journal, Nature.
    • In collaboration with Pfizer, we presented positive data at the International Conference on Clinical Trials for Alzheimer’s (CTAD) showing that its Cognitive Interference Processing technology differentiated between older healthy subjects positive for amyloid deposits in their brains (a primary biomarker for Alzheimer’s risk) vs. an age-matched comparison group of amyloid-negative subjects, both in change over time (p=0.04) and at the completion visit after a 28-day remote self-administration protocol (p<0.008).


  • Collaborations
    • We are working with top universities and premier partners in the healthcare space to bring our products to marketWe entered into a collaboration with Pfizer to test the ability of our technology to serve as a biomarker and cognitive enhancer in patients with prodromal (pre-symptomatic) Alzheimer’s disease (data presented at CTAD, see milestones above)
    • Shire Pharmaceuticals' (SHPG) Strategic Investment group, Merck Ventures V BV and Amgen Ventures are all investors in this program.
  • Expected Milestones and Timing
    • A regulatory filing for the ADHD digital therapeutic is anticipated with the U.S. Food and Drug Administration in the first half of 2018
    • Results are anticipated from our proof-of-concept clinical trial in depression
    • We are currently conducting multiple clinical trials of its digital medicine platform across a variety of patient populations, including autism spectrum disorder, depression, multiple sclerosis and Parkinson’s disease

The platform functions on the premise that advances in neuroscience research and consumer-facing technology are enabling a new way to sensitively measure neural function, and intervene in measured deficits, wherever the patient may be.  Our products address both quantitative measurement of and intensive intervention in cognitive functions in a variety of patient populations. The lead, patent-pending technology platform is based on cognitive science exclusively licensed from the lab of Dr. Adam Gazzaley at the University of California, San Francisco (UCSF), and proprietary adaptive algorithms developed by our team, all designed to be administered in the form of action video game interfaces. The platform powers both assessment (screens and monitors) and treatment products, which deploy real-time, adaptive cognitive challenges and interventions, respectively. 

Open-Label Proof of Concept Trial in Pediatric ADHD

Key Findings

Data: Efficacy Results from Open-Label Phase II Trial

Digital Biomarker Study in Healthy Subjects at Risk of Developing Alzheimer’s Disease

Key Findings

Data: Proprietary Akili AD Screen Reaction Time Metric